$PIII
P3 Health Partners Inc. Stock $piii

$piii Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000155837022015156 Filed on October 21, 2022

Income Statement

Concept	2022 Q2	2021 Q4	2021 Q2
Revenue	$269.5M	$58.76M	$303.0M
YoY Change	-11.07%	-52.94%	30.7%
Cost Of Revenue	$267.4M	$200.1M	$297.6M
YoY Change	-10.12%	45.79%	34.5%
Gross Profit	$2.006M	-$22.25M	$5.412M
YoY Change	-62.94%	79.74%	-48.85%
Gross Profit Margin	0.74%	-37.86%	1.79%
Selling, General & Admin	$42.51M	$17.35M	$34.08M
YoY Change	24.74%	-0.81%	45.73%
% of Gross Profit	2119.39%		629.61%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$42.88M	$187.6K	$762.4K
YoY Change	5524.67%	3.14%	107.26%
% of Gross Profit	2138.08%		14.09%
Operating Expenses	$1.182B	$117.7M	$37.84M
YoY Change	3022.83%	-7621.42%	77.04%
Operating Profit	-$912.2M	-$58.89M	-$32.43M
YoY Change	2713.09%	444.57%	200.46%
Interest Expense	-$2.734M	$2.131M	-$8.487M
YoY Change	-67.79%	-168.91%	86.08%
% of Operating Profit
Other Income/Expense, Net	$9.081M	$949.7K	-$10.66M
YoY Change	-185.18%	-426.73%
Pretax Income	-$903.1M	-$57.94M	-$51.58M
YoY Change	1651.04%	308.1%	235.92%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$154.3M	-$10.08M	-$46.33M
YoY Change	233.13%	-24.43%	320.17%
Net Earnings / Revenue	-57.28%	-17.16%	-15.29%
Basic Earnings Per Share	-$3.71	-$0.24
Diluted Earnings Per Share	-$3.73	-$0.24	-$190.2K
COMMON SHARES
Basic Shares Outstanding	41.58M	41.58M
Diluted Shares Outstanding	242.1M	41.58M

Balance Sheet

Concept	2022 Q2	2021 Q4	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$63.15M	$140.5M	$580.0K
YoY Change	10787.13%
Cash & Equivalents	$63.15M	$140.5M	$16.32M
Short-Term Investments
Other Short-Term Assets	$5.834M	$7.315M	$240.0K
YoY Change	2330.86%
Inventory
Prepaid Expenses		$355.2K
Receivables	$101.7M	$51.34M
Other Receivables	$261.9K	$726.9K
Total Short-Term Assets	$171.0M	$199.9M	$820.0K
YoY Change	20751.11%	50502.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.293M	$8.048M
YoY Change		30.85%
Goodwill	$458.3M	$1.310B
YoY Change		150251.06%
Intangibles	$793.6M	$835.8M
YoY Change
Long-Term Investments
YoY Change
Other Assets		$10.61M	$316.3M
YoY Change
Total Long-Term Assets	$1.273B	$2.164B	$316.3M
YoY Change	302.59%
TOTAL ASSETS
Total Short-Term Assets	$171.0M	$199.9M	$820.0K
Total Long-Term Assets	$1.273B	$2.164B	$316.3M
Total Assets	$1.444B	$2.364B	$317.1M
YoY Change	355.47%	598469.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$20.36M	$124.5M
YoY Change
Accrued Expenses	$49.95M	$52.91M	$190.0K
YoY Change	26188.2%	2314469.99%
Deferred Revenue
YoY Change
Short-Term Debt	$1.178M	$3.579M
YoY Change
Long-Term Debt Due	$0.00	$46.10K
YoY Change		-48.77%
Total Short-Term Liabilities	$228.8M	$198.8M	$190.0K
YoY Change	120337.31%	53298.41%
LONG-TERM LIABILITIES
Long-Term Debt	$80.00M	$80.00M
YoY Change		76.26%
Other Long-Term Liabilities	$19.68M	$21.17M	$15.73M
YoY Change	25.1%
Total Long-Term Liabilities	$99.68M	$101.2M	$15.73M
YoY Change	533.69%	82.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$228.8M	$198.8M	$190.0K
Total Long-Term Liabilities	$99.68M	$101.2M	$15.73M
Total Liabilities	$328.5M	$299.9M	$15.92M
YoY Change	1963.5%	80475.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$204.3M	-$39.42M
YoY Change		1724227.38%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$108.6M	$273.6M	$301.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.444B	$2.364B	$317.1M
YoY Change	355.47%	598469.09%

Cashflow Statement

Concept	2022 Q2	2021 Q4	2021 Q2
OPERATING ACTIVITIES
Net Income	-$154.3M	-$10.08M	-$46.33M
YoY Change	233.13%	-24.43%	320.17%
Depreciation, Depletion And Amortization	$42.88M	$187.6K	$762.4K
YoY Change	5524.67%	3.14%	107.26%
Cash From Operating Activities	-$45.31M	-$15.34M	-$660.0K
YoY Change	6765.54%	-14.53%
INVESTING ACTIVITIES
Capital Expenditures	-$523.3K	$120.6K
YoY Change		-117.37%
Acquisitions
YoY Change
Other Investing Activities	$272.2K	-$47.76M	$0.00
YoY Change		8196.58%
Cash From Investing Activities	-$251.1K	-$47.86M	$0.00
YoY Change		3669.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.320M
YoY Change
Debt Paid & Issued, Net		$8.008K
YoY Change
Cash From Financing Activities	-1.239M	198.7M	-40.00K
YoY Change	2997.48%	471.21%
NET CHANGE
Cash From Operating Activities	-45.31M	-15.34M	-660.0K
Cash From Investing Activities	-251.1K	-47.86M	0.000
Cash From Financing Activities	-1.239M	198.7M	-40.00K
Net Change In Cash	-46.80M	135.5M	-700.0K
YoY Change	6586.1%	770.6%
FREE CASH FLOW
Cash From Operating Activities	-$45.31M	-$15.34M	-$660.0K
Capital Expenditures	-$523.3K	$120.6K
Free Cash Flow	-$44.79M	-$15.46M
YoY Change		-10.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Entity Central Index Key EntityCentralIndexKey	0001832511
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q1	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	piii	Term For Reconciliation And Distribution Of Reserve Following Each Year End TermForReconciliationAndDistributionOfReserveFollowingEachYearEnd	P21M
	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://www.p3hp.org/20220630#MarkToMarketAdjustmentOfForesightStockWarrants
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	84000000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	84000000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	84000000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	84000000
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40033
	dei	Entity Registrant Name EntityRegistrantName	P3 Health Partners Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2992794
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2370 Corporate Circle Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89074
	dei	City Area Code CityAreaCode	702
	dei	Local Phone Number LocalPhoneNumber	910–3950
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63145379
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	753920
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	356286
CY2022Q2	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	99806410
CY2021Q4	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	50251004
CY2022Q2	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	1931291
CY2021Q4	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	1090104
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	261935
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	726903
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5080149
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6959067
CY2022Q2	us-gaap	Assets Current AssetsCurrent	170979084
CY2021Q4	us-gaap	Assets Current AssetsCurrent	199860950
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9630761
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8230250
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1337796
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	182321
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8292965
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047929
CY2022Q2	us-gaap	Goodwill Goodwill	458294462
CY2021Q4	us-gaap	Goodwill Goodwill	1309750216
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	793553591
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	835838605
CY2022Q2	piii	Notes Receivable Noncurrent NotesReceivableNoncurrent	3579220
CY2021Q4	piii	Notes Receivable Noncurrent NotesReceivableNoncurrent	3590715
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9510518
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7020045
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1273230756
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2164247510
CY2022Q2	us-gaap	Assets Assets	1444209840
CY2021Q4	us-gaap	Assets Assets	2364108460
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	20693070
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17730683
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3263338
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	6304362
CY2022Q2	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	18022395
CY2021Q4	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	22548694
CY2022Q2	piii	Claims Payable Current ClaimsPayableCurrent	139322367
CY2021Q4	piii	Claims Payable Current ClaimsPayableCurrent	101958324
CY2022Q2	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	35021557
CY2021Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	37835642
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	11329930
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8771065
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	46101
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1178229
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	3578561
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	228830886
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	198773432
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10575753
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6296883
CY2022Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	5429009
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	11382826
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3674192
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3486593
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	99678954
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	101166302
CY2022Q2	us-gaap	Liabilities Liabilities	328509840
CY2021Q4	us-gaap	Liabilities Liabilities	299939734
CY2022Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1007075525
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1790617285
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5495125
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4494049
CY2022Q2	piii	Mark To Market Adjustment Of Foresight Stock Warrants MarkToMarketAdjustmentOfForesightStockWarrants	-11815093
CY2021Q2	piii	Mark To Market Adjustment Of Foresight Stock Warrants MarkToMarketAdjustmentOfForesightStockWarrants	1123583
	piii	Mark To Market Adjustment Of Foresight Stock Warrants MarkToMarketAdjustmentOfForesightStockWarrants	-5953817
	piii	Mark To Market Adjustment Of Foresight Stock Warrants MarkToMarketAdjustmentOfForesightStockWarrants	10661579
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	312945752
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	312945752
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-204345577
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39418124
CY2022Q2	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	108624475
CY2021Q4	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	273551441
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1444209840
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2364108460
CY2022Q2	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2021Q2	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	269453971
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144586444
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	542998305
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	295884386
CY2022Q2	piii	Medical Expenses MedicalExpenses	267448368
CY2021Q2	piii	Medical Expenses MedicalExpenses	150380517
	piii	Medical Expenses MedicalExpenses	533269170
	piii	Medical Expenses MedicalExpenses	297005022
CY2022Q2	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-1489571
CY2021Q2	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	1000000
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-2814084
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	3000000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41098400
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18390659
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79697812
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33449735
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1408096
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	356501
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2272626
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	626742
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851455754
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851455754
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21720081
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	429830
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43471912
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	762378
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1181641128
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	170557507
	us-gaap	Operating Expenses OperatingExpenses	1507353190
	us-gaap	Operating Expenses OperatingExpenses	334843877
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-912187157
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-25971063
	us-gaap	Operating Income Loss OperatingIncomeLoss	-964354885
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38959491
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2733875
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2369764
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9081218
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3493347
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	458692
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15155628
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-903105939
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29464410
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-963896193
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54115119
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-903105939
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-29464410
	us-gaap	Profit Loss ProfitLoss	-963896193
	us-gaap	Profit Loss ProfitLoss	-54115119
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-748755990
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-798968740
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-154349949
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-29464410
	us-gaap	Net Income Loss NetIncomeLoss	-164927453
	us-gaap	Net Income Loss NetIncomeLoss	-54115119
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.97
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.01
CY2020Q4	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	-130217705
CY2021Q1	us-gaap	Partners Capital Account Unit Based Compensation PartnersCapitalAccountUnitBasedCompensation	460515
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-24650712
CY2021Q1	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	-154407902
CY2021Q2	us-gaap	Partners Capital Account Unit Based Compensation PartnersCapitalAccountUnitBasedCompensation	563792
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-29464410
CY2021Q2	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	-183308520
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	273551441
CY2022Q1	piii	Stock Issued Value Stock Compensation Awards Vesting StockIssuedValueStockCompensationAwardsVesting	55
CY2022Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-10577504
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	262973992
CY2022Q2	piii	Stock Issued Value Stock Compensation Awards Vesting StockIssuedValueStockCompensationAwardsVesting	432
CY2022Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-154349949
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	108624475
	us-gaap	Profit Loss ProfitLoss	-963896193
	us-gaap	Profit Loss ProfitLoss	-54115119
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43471912
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	762378
	us-gaap	Share Based Compensation ShareBasedCompensation	15426980
	us-gaap	Share Based Compensation ShareBasedCompensation	1024307
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851455754
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	349324
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	621305
	piii	Mark To Market Adjustment Of Stock Warrants MarkToMarketAdjustmentOfStockWarrants	-5953817
	piii	Mark To Market Adjustment Of Stock Warrants MarkToMarketAdjustmentOfStockWarrants	10661579
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-2814084
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	3000000
	us-gaap	Paid In Kind Interest PaidInKindInterest	187599
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	376219
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-92491
	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	49555406
	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	-1212093
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1890414
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	361241
	piii	Net Change In Rights Of Use Assets And Liabilities NetChangeInRightsOfUseAssetsAndLiabilities	3556272
	piii	Net Change In Rights Of Use Assets And Liabilities NetChangeInRightsOfUseAssetsAndLiabilities	75337
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1163574
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1005876
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3041024
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2648873
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2558865
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1807007
	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	-4526299
	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	-1342803
	piii	Increase Decrease In Claims Payables IncreaseDecreaseInClaimsPayables	37364043
	piii	Increase Decrease In Claims Payables IncreaseDecreaseInClaimsPayables	5736206
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73087629
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34131885
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1400511
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1883226
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	82000
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-226808
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1400511
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1738418
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	12750000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2446433
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	44629
	piii	Payment For Loan Origination And Closing Fees PaymentForLoanOriginationAndClosingFees	-191250
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2446433
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12514121
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76934573
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23356182
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140833872
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39902947
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63899299
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16546765
CY2022Q2	piii	Number Of Health Plans Agreements Entered NumberOfHealthPlansAgreementsEntered	20
CY2021Q4	piii	Number Of Health Plans Agreements Entered NumberOfHealthPlansAgreementsEntered	17
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-903105939
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29464410
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63145379
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
	piii	Health Plans Term Of Contract HealthPlansTermOfContract	P1M
CY2022Q2	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	18022395
CY2021Q4	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	22548694
	piii	Number Of Revenue Practical Expedients Elected NumberOfRevenuePracticalExpedientsElected	2
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Management’s Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires Management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.</p>
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63145379
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2021Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63145379
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	753920
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	356286
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63899299
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140833872
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16322893
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	223872
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16546765
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851500000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	369698137
	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-173796294
	piii	Business Acquisition Pro Forma Net Income Loss Attributable To Noncontrolling Interest BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest	-143555739
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-30240555
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63145379
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140477586
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	753920
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	356286
CY2022Q2	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	1931291
CY2021Q4	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	1090104
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	261935
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	726903
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	20693070
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17730683
CY2022Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	5429009
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	11382826
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	502276
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6316605
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-344101
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	10661579
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	158175
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16978184
CY2022Q2	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss Current ContractWithCustomerReceivableBeforeAllowanceForCreditLossCurrent	2698072
CY2021Q4	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss Current ContractWithCustomerReceivableBeforeAllowanceForCreditLossCurrent	2641182
CY2022Q2	us-gaap	Contract With Customer Receivable Allowance For Credit Loss Current ContractWithCustomerReceivableAllowanceForCreditLossCurrent	2129238
CY2021Q4	us-gaap	Contract With Customer Receivable Allowance For Credit Loss Current ContractWithCustomerReceivableAllowanceForCreditLossCurrent	1968750
CY2022Q2	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	568834
CY2021Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	672432
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9630761
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8230250
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1337796
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	182321
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8292965
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047929
CY2021Q4	us-gaap	Goodwill Goodwill	1309750216
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851455754
CY2022Q2	us-gaap	Goodwill Goodwill	458294462
CY2022Q2	us-gaap	Goodwill Goodwill	458294462
CY2021Q4	us-gaap	Goodwill Goodwill	1309750216
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0
	piii	Term Of Steady Decline In Share Price TermOfSteadyDeclineInSharePrice	P3M
	piii	Percentage Of Stock Lower Than Opening Price PercentageOfStockLowerThanOpeningPrice	0.63
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851500000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	835838605
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42285014
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	793553591
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	84000000
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P9Y4M24D
CY2022Q2	piii	Financing Receivable Number Of Promissory Notes Entered FinancingReceivableNumberOfPromissoryNotesEntered	5
CY2022Q2	piii	Financing Receivable Number Of Family Medical Practices With Whom Promissory Notes Are Entered FinancingReceivableNumberOfFamilyMedicalPracticesWithWhomPromissoryNotesAreEntered	3
CY2022Q2	piii	Financing Receivable Separate Provider Agreements With Each Practice Related To Number Of Promissory Notes Entered FinancingReceivableSeparateProviderAgreementsWithEachPracticeRelatedToNumberOfPromissoryNotesEntered	4
CY2022Q2	piii	Financing Receivable Number Of Promissory Notes Entered FinancingReceivableNumberOfPromissoryNotesEntered	5
CY2022Q2	piii	Financing Receivable Separate Provider Agreements With Each Practice Related To Number Of Promissory Notes Entered FinancingReceivableSeparateProviderAgreementsWithEachPracticeRelatedToNumberOfPromissoryNotesEntered	4
CY2022Q2	us-gaap	Notes Receivable Net NotesReceivableNet	3729220
CY2022Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	150000
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	3590715
CY2022Q2	us-gaap	Financing Receivable Accrued Interest Before Allowance For Credit Loss FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss	1006898
CY2021Q4	us-gaap	Financing Receivable Accrued Interest Before Allowance For Credit Loss FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss	885243
CY2022Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	659958
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	526808
CY2022Q2	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	139322367
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	101958324
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Unpaid, Beginning of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,958,324</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incurred, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 468,944,879</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,097,685</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Incurred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 476,042,564</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paid, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340,629,168</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,049,353</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 438,678,521</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Unpaid Assumed in Acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Unpaid, End of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,322,367</p></td></tr></table>
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	101958324
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	468944879
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	7097685
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	476042564
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	340629168
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	98049353
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	438678521
CY2022Q2	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	139322367
	piii	Security Agreement Lenders Collateral Percentage Of Pledged Stock Its Subsidiaries And Bank Accounts SecurityAgreementLendersCollateralPercentageOfPledgedStockItsSubsidiariesAndBankAccounts	1
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	80046101
	us-gaap	Repayments Of Debt RepaymentsOfDebt	46101
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	80000000
CY2022Q2	piii	Long Term Debt Paid In Kind Interest Maturity Remainder Of Fiscal Year LongTermDebtPaidInKindInterestMaturityRemainderOfFiscalYear	2660461
CY2022Q2	piii	Long Term Debt Cash Interest Maturity Remainder Of Fiscal Year LongTermDebtCashInterestMaturityRemainderOfFiscalYear	2788374
CY2022Q2	piii	Long Term Debt Total Payments Maturity Remainder Of Fiscal Year LongTermDebtTotalPaymentsMaturityRemainderOfFiscalYear	2788374
CY2022Q2	piii	Long Term Debt Paid In Kind Interest Maturity Year One LongTermDebtPaidInKindInterestMaturityYearOne	5624513
CY2022Q2	piii	Long Term Debt Cash Interest Maturity Year One LongTermDebtCashInterestMaturityYearOne	5675461
CY2022Q2	piii	Long Term Debt Total Payments Maturity Year One LongTermDebtTotalPaymentsMaturityYearOne	5675461
CY2022Q2	piii	Long Term Debt Paid In Kind Interest Maturity Year Two LongTermDebtPaidInKindInterestMaturityYearTwo	6061814
CY2022Q2	piii	Long Term Debt Cash Interest Maturity Year Two LongTermDebtCashInterestMaturityYearTwo	5882309
CY2022Q2	piii	Long Term Debt Total Payments Maturity Year Two LongTermDebtTotalPaymentsMaturityYearTwo	5882309
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	65000000
CY2022Q2	piii	Long Term Debt Paid In Kind Interest Maturity Year Three LongTermDebtPaidInKindInterestMaturityYearThree	6274526
CY2022Q2	piii	Long Term Debt Cash Interest Maturity Year Three LongTermDebtCashInterestMaturityYearThree	19518225
CY2022Q2	piii	Long Term Debt Total Payments Maturity Year Three LongTermDebtTotalPaymentsMaturityYearThree	84518225
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	15000000
CY2022Q2	piii	Long Term Debt Paid In Kind Interest Maturity Year Four LongTermDebtPaidInKindInterestMaturityYearFour	1851284
CY2022Q2	piii	Long Term Debt Cash Interest Maturity Year Four LongTermDebtCashInterestMaturityYearFour	20054451
CY2022Q2	piii	Long Term Debt Total Payments Maturity Year Four LongTermDebtTotalPaymentsMaturityYearFour	35054451
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	80000000
CY2022Q2	piii	Long Term Debt Paid In Kind Interest Maturity LongTermDebtPaidInKindInterestMaturity	22472598
CY2022Q2	piii	Long Term Debt Cash Interest Maturity LongTermDebtCashInterestMaturity	53918820
CY2022Q2	piii	Long Term Debt Total Payments Maturity LongTermDebtTotalPaymentsMaturity	133918820
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	80000000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	80046101
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	46101
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	80000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851500000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	9037319
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2034279
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.43
	piii	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P3Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	66667
	piii	Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice	5.02
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1967612
CY2022Q2	piii	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	6.48
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y9M7D
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-903105939
	us-gaap	Profit Loss ProfitLoss	-963896193
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-748755990
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-798968740
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-154349949
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-164927453
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-154349949
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-164927453
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-748755990
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-798968740
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-903105939
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-963896193
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41578890
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41578890
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.97
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41578890
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41578890
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	200473866
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	198782864
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	242052756
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	240361754
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.01
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13554998
CY2020Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	0
CY2022Q2	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	35021557
CY2021Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	37835642
	piii	Number Of Operating Lease NumberOfOperatingLease	1
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	735039
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	563651
	us-gaap	Operating Lease Cost OperatingLeaseCost	1473710
	us-gaap	Operating Lease Cost OperatingLeaseCost	1051963
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M28D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M21D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.112
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.104
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	419351
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2117494
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2716584
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2366864
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1762184
CY2022Q2	piii	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	3973507
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13355984
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2447475
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	10908509
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	332756
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2087235
	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	0
CY2021	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	0
CY2021	piii	Number Of Health Plans Resulting In Renegotiation NumberOfHealthPlansResultingInRenegotiation	1
CY2022Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10600000
	piii	Percentage Of Total Revenues Recurring PercentageOfTotalRevenuesRecurring	0.97
CY2021	piii	Percentage Of Total Revenues Recurring PercentageOfTotalRevenuesRecurring	0.97
	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	84000000.0
CY2021Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	25882296
	us-gaap	Loans And Leases Receivable Related Parties Additions LoansAndLeasesReceivableRelatedPartiesAdditions	2223912
	us-gaap	Loans And Leases Receivable Related Parties Period Increase Decrease LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease	437236
CY2022Q2	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	28543444

Files In Submission

Name	View Source	Status
0001558370-22-015156-index-headers.html	Edgar Link	pending
0001558370-22-015156-index.html	Edgar Link	pending
0001558370-22-015156.txt	Edgar Link	pending
0001558370-22-015156-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
piii-20220630.xsd	Edgar Link	pending
piii-20220630x10q.htm	Edgar Link	pending
piii-20220630xex31d1.htm	Edgar Link	pending
piii-20220630xex31d2.htm	Edgar Link	pending
piii-20220630xex32d1.htm	Edgar Link	pending
piii-20220630xex32d2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
piii-20220630_def.xml	Edgar Link	unprocessable
piii-20220630_pre.xml	Edgar Link	unprocessable
piii-20220630_lab.xml	Edgar Link	unprocessable
piii-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
piii-20220630x10q_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIII
P3 Health Partners Inc. Stock $piii

2022 Q2 Form 10-Q Financial Statement

#000155837022015156 Filed on October 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII P3 Health Partners Inc. Stock $piii

2022 Q2 Form 10-Q Financial Statement

#000155837022015156 Filed on October 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII
P3 Health Partners Inc. Stock $piii